For example, the prognosis of patients with HER2-positive breast cancer has significantly improved as a result of the successful targeting of HER2 overexpression with monoclonal antibodies like trastuzumab (Herceptin) and pertuzumab (Perjeta) [12,16]. Here, ERBB2 is linked to breast cancer.